Xin Qiu

2 papers in the library · 451 citations · publishing 2020-2025

Papers

Esketamine Nasal Spray for Rapid Reduction of Depressive Symptoms in Patients With Major Depressive Disorder Who Have Active Suicide Ideation With Intent: Results of a Phase 3, Double-Blind, Randomized Study (ASPIRE II)

The International Journal of Neuropsychopharmacology August 26, 2020 Dawn F. Ionescu, Dong-Jing Fu, Xin Qiu et al. 411 citations

In severely depressed adults with active suicidal thoughts and intent, adding esketamine nasal spray to standard care (hospitalization and new antidepressants) produced a greater reduction in depressive symptoms than placebo plus standard care. At 24 hours, depression scores dropped an average of 15.7 points with esketamine versus 12.4 points with placebo. Improvement was also seen at 4 hours. Both groups showed rapid decreases in suicidality severity, but the difference between them was not statistically significant. Common side effects of esketamine included dizziness, dissociation, nausea, and headache.

DOI: 10.1093/ijnp/pyaa068 Full text Major depressive disorder Clinical global impression Placebo Randomized controlled trial +9

Esketamine Monotherapy in Adults With Treatment-Resistant Depression: A Randomized Clinical Trial.

JAMA Psychiatry July 2, 2025 Adam Janik, Xin Qiu, Rosanne Lane et al. 40 citations

In adults with treatment-resistant depression who had not responded to at least two prior oral antidepressants, esketamine nasal spray taken alone (without an oral antidepressant) reduced depressive symptoms more than a placebo. Over four weeks, both a 56 mg and an 84 mg dose of esketamine produced significantly greater improvements on the Montgomery-Åsberg Depression Rating Scale than placebo, with effects apparent as early as 24 hours after the first dose. Common side effects included nausea, dissociation, dizziness, and headache. The findings suggest that esketamine monotherapy could offer a new treatment option for patients who cannot tolerate or do not respond to oral antidepressants.

DOI: 10.1001/jamapsychiatry.2025.1317 Full text Esketamine nasal spray Treatment-resistant depression Depression treatment Antidepressant therapy +35